8-K: Allarity Therapeutics Announces 1-for-20 Reverse Stock Split to Regain Nasdaq Compliance

Allarity Therapeutics will implement a 1-for-20 reverse stock split effective April 9, 2024, to regain compliance with Nasdaq's minimum bid price requirement.

Summary

• Allarity Therapeutics has announced a 1-for-20 reverse stock split of its common stock.
• The reverse stock split will be effective on April 9, 2024, at 9:30 a.m. Eastern Time.
• The company's stock will begin trading on a split-adjusted basis when the market opens on April 9, 2024.
• This move is intended to regain compliance with Nasdaq's minimum bid price requirement.
• The total number of outstanding shares will be reduced to approximately one-twentieth of the pre-split amount.
• No fractional shares will be issued; instead, fractional shares will be rounded up to the nearest whole share.
• Adjustments will be made to outstanding equity awards, the number of shares issuable under the 2021 equity incentive plan, and the conversion or exercise prices of such awards and plans.
• The reverse stock split will not change the number of authorized shares or the par value per share.
• Computershare Limited has been appointed as the exchange agent to facilitate the reverse stock split process.

Sentiment

Score: 5

Explanation: The sentiment is neutral to slightly negative. While the reverse stock split is a necessary step to maintain Nasdaq listing, it also highlights the company's struggle with its share price. The company also faces significant risks related to clinical trials and funding.

Positives

• The reverse stock split is a strategic move to regain compliance with Nasdaq's minimum bid price requirement, which is crucial for maintaining the company's listing.
• Rounding up fractional shares to the nearest whole share is beneficial for shareholders who would otherwise receive a fractional share.
• The company has appointed Computershare Limited as the exchange agent to facilitate the process, ensuring a smooth transition for shareholders.

Negatives

• The reverse stock split reduces the number of outstanding shares, which can be perceived negatively by some investors.
• The need for a reverse stock split indicates that the company's share price has fallen below the Nasdaq minimum bid price requirement, which is a sign of poor performance.

Risks

• There is a risk that the reverse stock split may not be sufficient to maintain the company's listing on Nasdaq.
• The trading price of Allarity's shares may be volatile.
• The company faces risks related to raising sufficient capital to support its clinical trials.
• Clinical trial results may change following more comprehensive reviews of the data.
• There is a risk of delays or cessation of clinical trials.
• The company faces risks related to regulatory approval and commercialization of its products.
• The COVID-19 pandemic could impact the company's clinical trials and operations.

Future Outlook

The company aims to regain compliance with the Nasdaq minimum bid price requirement through the reverse stock split. However, the company acknowledges risks related to maintaining its listing, raising capital, and the success of its clinical trials.

Management Comments

• The reverse stock split is a strategic move to regain compliance with the Nasdaq minimum bid price requirement.
• The Board of Directors approved the implementation of a 1-for-20 reverse stock split.

Industry Context

Reverse stock splits are a common strategy for companies facing delisting from major exchanges due to low share prices. This action is often seen in the biotechnology and pharmaceutical sectors, where companies may experience volatility due to the nature of clinical trials and regulatory approvals.

Comparison to Industry Standards

• Reverse stock splits are a common mechanism used by companies in the biotechnology sector to maintain listing compliance, particularly when facing low share prices.
• Other companies in the pharmaceutical industry, such as those developing novel therapies, have also used reverse stock splits to meet exchange requirements.
• The 1-for-20 ratio is within the typical range for reverse stock splits, which can vary depending on the specific circumstances of the company and the exchange requirements.

Stakeholder Impact

• Shareholders will see a reduction in the number of shares they own, but the value of their holdings should remain the same immediately after the split.
• The reverse stock split is intended to benefit shareholders by maintaining the company's listing on Nasdaq.
• The company's employees may be impacted by the company's financial performance and the success of its clinical trials.

Next Steps

• The reverse stock split will be implemented on April 9, 2024.
• The company will continue to work on its clinical trials and development of its product candidates.
• Shareholders holding shares in certificate form will receive instructions from Computershare on how to exchange their certificates.

Key Dates

Keywords

reverse stock split, Nasdaq compliance, minimum bid price, stock split, Allarity Therapeutics, ALLR, pharmaceutical, clinical-stage, cancer treatment, DRP, stenoparib